M1 Kliniken AG Achieves Strong 2024 Results, Targets Further Growth

M1 Kliniken AG received a positive update from First Berlin Equity Research. Analyst Ellis Acklin reaffirmed his BUY recommendation for M1 Kliniken, with a target price of €28. The 2024 audited report exceeded forecasts, with EBIT surpassing predictions by 13%. The group's revenue rose to €339 million, marking a 7% increase from the previous year. Notably, the Beauty segment sales increased by 30%, reaching €92 million.

The first quarter of 2025 continued this positive trajectory, with group sales increasing by 10% to €93 million. The Beauty segment spearheaded this growth, showing a 4% rise in turnover. Consequently, segment EBIT rose by 24% to €7 million. M1 Kliniken plans to propose a €0.50 dividend at the upcoming AGM, while also focusing on further domestic and international expansion.

The company remains resilient amidst geopolitical uncertainties, asserting its ability to perform well during economic challenges. M1's focus on affordable injectables positions it favorably for future growth.